Crystal-Induced Arthritis Clinical Trial
— FUMBLEOfficial title:
Features of Microcrystalline Polyarthritis Treated by Biologics and Evolution - FUMBLE Study
NCT number | NCT04005625 |
Other study ID # | 29BRC19.0056 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 1, 2019 |
Est. completion date | June 1, 2020 |
Verified date | September 2020 |
Source | University Hospital, Brest |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The study will involve adult patient who had received any biologic agent for microcrystalline
disease in western France (Tours, Le Mans, Orléans, Angers, Rennes, Poitiers et Brest)
between 01/01/2010 and 31/12/2018.
Investigators will answer retrospectively a questionnaire that covers patient and disease
data, biologic agent use, efficacy and adverse events.
Status | Completed |
Enrollment | 46 |
Est. completion date | June 1, 2020 |
Est. primary completion date | June 1, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Crystal- induced arthritis - Treatment by biologic - In western France Exclusion Criteria: - None |
Country | Name | City | State |
---|---|---|---|
France | CHRU de Brest | Brest |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Brest |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Treatment duration | Duration of treatment by biologic in days | one year | |
Secondary | number of synovitis | number of synovitis on 44 | inclusion |